Ku‐Lung Hsu

The paper demonstrates that liposomal DAGLβ inhibitor KT109 shows significantly higher antinociceptive potency in neuropathic pain models, mediated by AMPK activation.

The paper investigates paralog-specific effects of DGK inhibitors on PA generation during PLC signaling in live cells, finding that BMS-502 inhibits PA production while R59022 paradoxically increases it.

This paper develops a covalent PFKL activator that disrupts cancer cell metabolism and delivers a cytotoxic payload, showing efficacy in vitro and in vivo.

The paper develops a chemoproteomics platform to map the human purine interactome and identifies a regioselective ligand for ACAT2 with potential therapeutic applications in cancer.

This study uses HS-AFM and simulations to show ligand-dependent assembly switching of human PFKL, revealing structural changes in response to ATP and F6P.

The paper develops PhAzE chemistry to selectively target serine hydrolases in vivo with minimal toxicity, demonstrating the potential of stereogenic P(V) compounds for protein ligand discovery.

The paper shows acetaminophen inhibits DAGLα, reducing 2-arachidonoyl glycerol production and suggesting a novel antinociceptive mechanism involving DAGLα/CB1 circuits.

This study identifies ISL2 as an epigenetically silenced tumor suppressor in pancreatic cancer that regulates metabolism and presents therapeutic vulnerabilities.